Array Biopharma, now a wholly owned subsidiary of Pfizer

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Array Biopharma, now a wholly owned subsidiary of Pfizer sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).

21 total trials none currently recruiting 19 completed early-phase tilt top decile by trial count

Array Biopharma, now a wholly owned subsidiary of Pfizer: 21 sponsored US clinical trials, none currently recruiting.

Array Biopharma, now a wholly owned subsidiary of Pfizer sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 19 completed. 0 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 2 trials.

Top-decile sponsor footprint

Array Biopharma, now a wholly owned subsidiary of Pfizer ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 66/100

19 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

21 total, page 1 of 1

TERMINATED Phase 1

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function

NCT02050815
TERMINATED Phase 1

A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma

NCT01801358
COMPLETED Phase 1

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01649336
COMPLETED Phase 1

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

NCT01496495
COMPLETED Phase 1

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

NCT01363232
COMPLETED Phase 1

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

NCT01352273
COMPLETED Phase 1

A Safety Study of ARRY-502 in Healthy Subjects

NCT01349725
COMPLETED Phase 1

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

NCT01316822
COMPLETED Phase 1

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

NCT01248923
COMPLETED Phase 1

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

NCT00952198
COMPLETED Phase 1

A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer

NCT00959127
COMPLETED Phase 1

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome

NCT00916227
COMPLETED Phase 1

A Safety Study of ARRY-300 in Healthy Subjects

NCT00828165
COMPLETED Phase 1

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

NCT00833326
COMPLETED Phase 1

A Safety Study of ARRY-371797 in Healthy Subjects

NCT00790049
COMPLETED Phase 1

A Study of ARRY-371797 in Patients With Rheumatoid Arthritis

NCT00729209
COMPLETED Phase 1

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

NCT00710736
COMPLETED Phase 2

A Study of ARRY-438162 in Patients With Rheumatoid Arthritis

NCT00650767
COMPLETED Phase 1

A Study of ARRY-520 in Patients With Advanced Cancer

NCT00462358
COMPLETED Phase 1

A Study of ARRY-334543 in Patients With Advanced Cancer

NCT00278902
COMPLETED Phase 1

A Study of ARRY-142886 in Patients With Advanced Cancer

NCT00085787

Phase Distribution

PhaseTrial count
Phase 1 20
Phase 2 1

Therapeutic Areas

Healthy 2
Type 2 Diabetes 1
Advanced Cancer 1
Advanced Solid Tumors 1

How the Array Biopharma, now a wholly owned subsidiary of Pfizer early-phase archive is shaped

21 indexed studies, none listed as recruiting (0% open); 19 completed (90%).

Phase mix: 0 late (III/IV) vs 21 early (I/II) (early-phase heavy).

Top condition: Healthy (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Array Biopharma, now a wholly owned subsidiary of Pfizer: archived-pipeline peers nationwide

Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Array Biopharma, now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0510152025 0%5%10%15%20% Total trials Recruiting share Array Biopharma, now a wholly owned subsidiary of PfizerAEterna ZentarisAmphastar PharmaceuticalsApellis PharmaceuticalsBasilea Pharmaceutica10xBio22nd Century Group23andMe3-C Institute for Social Development
Array Biopharma, now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Array Biopharma, now a wholly owned subsidiary of Pfizer sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 21 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Array Biopharma, now a wholly owned subsidiary of Pfizer page

21 registered trials is a research-attention snapshot, not an endorsement of Array Biopharma, now a wholly owned subsidiary of Pfizer or any single study.

  • None of Array Biopharma, now a wholly owned subsidiary of Pfizer's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Array Biopharma, now a wholly owned subsidiary of Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Array Biopharma, now a wholly owned subsidiary of Pfizer pipeline card: 21 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.